The Real‐World Safety Profile of Immune Checkpoint Inhibitors in Melanoma: FAERS Pharmacovigilance Analysis Complemented by Randomized Trial Evidence
Yiwei Chen, Xueyan Liang, Xiaoyu Chen, Yan Li · 2026
Read The Real‐World Safety Profile of Immune Checkpoint Inhibitors in Melanoma: FAERS Pharmacovigilance Analysis Complemented by Randomized Trial Evidence by Yiwei Chen, Xueyan Liang, Xiaoyu Chen, Yan Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13412547.txt.
Description
Yiwei Chen and co-authors compare the safety of immune checkpoint inhibitors in melanoma in 2026 by pairing trial evidence with real-world harm reports. These drugs work well against melanoma, yet their side-effect profiles differ and head-to-head safety data are thin. A Bayesian network meta-analysis covered 31 randomized trials with 11,937 patients, and a parallel search mined the United States FAERS database for reports filed between 2004 and 2023.
Ipilimumab, nivolumab, and pembrolizumab ranked lowest for treatment-related harms of any grade in the trial network. The reports database held 5,974 adverse events among 4,599 treated melanoma patients, with 236 event terms significantly tied to the drug class. The authors offer the signals for monitoring, not firm prescribing rules.
Catalog record
| CREATOR | Yiwei Chen, Xueyan Liang, Xiaoyu Chen, Yan Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |